Details for New Drug Application (NDA): 021513
✉ Email this page to a colleague
The generic ingredient in ENABLEX is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
Summary for 021513
Tradename: | ENABLEX |
Applicant: | Abbvie |
Ingredient: | darifenacin hydrobromide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 22, 2004 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 22, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021513
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-001 | Dec 22, 2004 | 5,096,890 | ⤷ Subscribe |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-002 | Dec 22, 2004 | 6,106,864 | ⤷ Subscribe |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-002 | Dec 22, 2004 | 5,096,890 | ⤷ Subscribe |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-001 | Dec 22, 2004 | 6,106,864 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription